Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of Long-Acting Injectable Cabotegravir/Rilpivirine for the Treatment of HIV in Belgium

NCT06424964 is registered in ClinicalTrials.gov with Belgian Research on AIDS and HIV Consortium as lead sponsor.

NCT NCT06424964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06424964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of Long-Acting Injectable Cabotegravir/Rilpivirine for the Treatment of HIV in Belgium
Lead sponsor
Belgian Research on AIDS and HIV Consortium
Phase
Observational
Overall status
Recruiting
Start date
January 13, 2025
Completion date
July 31, 2025
Enrollment
600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus